<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OXCARBAZEPINE</span><br/>(ox-car'ba-ze-peen)<br/><span class="topboxtradename">Trileptal<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant</span><br/><b>Prototype: </b>Carbamazepine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 300 mg, 600 mg tablets; 300 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally related to tricyclic antidepressants (TCAs) but lacks antidepressant properties. Anticonvulsant properties may
         result from blockage of voltage-sensitive sodium channels, which results in stabilization of hyperexcited neural membranes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits repetitive neuronal firing, and decreased propagation of neuronal impulses.</p>
<h1><a name="uses">Uses</a></h1>
<p>Monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children age 416.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to oxcarbazepine; pregnancy (category C), lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults; renal impairment; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Partial Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 300 mg b.i.d. and increase by 600 mg/d q wk to 2400 mg/d in 2 divided doses for monotherapy or 1200 mg/d as adjunctive
               therapy<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>416 y</i>, Initiate with 810 mg/kg/d divided b.i.d. (max: 600 mg/d), gradually increase weekly to target dose (divided b.i.d.)
               based on weight: <i>2029 kg,</i> 900 mg/d; <i>29.139 kg,</i> 1200 mg/d; <i>&gt;39 kg,</i> 1800 mg/d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Initiate therapy at one-half the usual starting dose (300 mg/d) if creatinine clearance 
         </li><li>Do not abruptly stop this medication; withdraw drug gradually when discontinued to minimize seizure potential.</li>
<li>Store preferably at 25° C (77° F), but room temperature permitted. Keep container tightly closed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fatigue,</span> asthenia, peripheral edema, generalized edema, chest pain, weight gain. <span class="typehead">CV:</span> Hypotension. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, abdominal pain,</span> diarrhea, dyspepsia, constipation, gastritis, anorexia, dry mouth. <span class="typehead">Hematologic:</span> Lymphadenopathy. <span class="typehead">Metabolic:</span> Hyponatremia. <span class="typehead">Musculoskeletal:</span> Muscle weakness. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache, dizziness, somnolence, ataxia, nystagmus, abnormal gait,</span> insomnia, tremor, nervousness, agitation, abnormal coordination, speech disorder, confusion, abnormal thinking, aggravate
      convulsions, emotional lability. <span class="typehead">Respiratory:</span> Rhinitis, cough, bronchitis, pharyngitis. <span class="typehead">Skin:</span> Acne, hot flushes, purpura, <span class="speceff-life">Stevens-Johnson syndrome</span>, <span class="speceff-life">toxic epidermal necrolysis</span>. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Diplopia, vertigo, abnormal vision,</span> abnormal accommodation, taste perversion, ear ache. <span class="typehead">Urogenital:</span> Urinary tract infection, micturition frequency, vaginitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b> Carbamazepine,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>valproic acid,</b>
<b>verapamil, </b>
<span class="classification">calcium channel blockers</span> may decrease oxcarbazepine levels; may increase levels of <b>phenobarbital,</b>
<b>phenytoin;</b> may decrease levels of <b>felodipine,</b>
<span class="classification">oral contraceptives</span>. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease anticonvulsant effectiveness. <b>Evening primrose oil</b> may decrease the seizure threshold. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed from GI tract. <span class="typehead">Peak:</span> Steady-state levels reached in 23 d. <span class="typehead">Distribution:</span> 40% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver to active 10-monohydroxy metabolite (MHD). <span class="typehead">Elimination:</span> 95% excreted in kidneys. <span class="typehead">Half-Life:</span> 2 h, MHD 9 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report S&amp;S of: Hyponatremia (e.g., nausea, malaise, headache, lethargy, confusion); CNS impairment (e.g.,
            somnolence, excessive fatigue, cognitive deficits, speech or language problems, incoordination, gait disturbances).
         </li>
<li>Monitor phenytoin levels when administered concurrently.</li>
<li>Lab tests: Periodic serum sodium, T<sub>4</sub> level; when oxcarbazepine is used as adjunctive therapy, closely monitor plasma level of the concomitant antiepileptic drug
            during titration of the oxcarbazepine dose.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of the following: Dizziness, excess drowsiness, frequent headaches, malaise, double vision, lack of coordination,
            or persistent nausea.
         </li>
<li>Exercise special caution with concurrent use of alcohol or CNS depressants.</li>
<li>Use caution with potentially hazardous activities and driving until response to drug is known.</li>
<li>Use or add barrier contraceptive since drug may render hormonal methods ineffective.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>